These two compounds together form a synergistic blockade of the ability of SARS-CoV-2 to invade human cells (prophylaxis; per the paper in the Cell journal). If side-effects can be rapidly identified and minimal, it could be good bridge until a vaccine is developed (2 years+, high probability of yearly/semi-annual recurrent epidemics).<p>Camostat Mesylate / Camostat / 59721-29-8<p>- 100-200 mg p.c. (300-600 mg/daily)<p>- Used in Japan for postoperative reflux esophagitis & acute chronic pancreatitis<p>E-64d / Aloxistatin / Loxistatin / EP-453 / 88321-09-9<p>- Possibly 100-150 mg p.c. (300-450mg/daily)<p>- May increase risk of bleeding / bleeding strokes / reduce clotting / thin the blood<p>- Prices of this compound are currently very high but would hopefully reduce with scale and local synthesis